World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
103
Citations
46299
World Ranking
7266
National Ranking
275

Suresh Senan publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Suresh Senan sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 730 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Suresh Senan D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Suresh Senan sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Suresh Senan is affiliated with the University of Amsterdam in the Netherlands, focusing on medical research with specific expertise in oncology and radiotherapy. They have contributed extensively to the field of pulmonary and respiratory medicine as well as related subfields such as radiology, nuclear medicine and imaging, radiation, and surgery. Their scholarly output amounts to over 360 publications predominantly centered on medicine.

The scientist's primary research interests encompass topics relevant to lung cancer diagnosis and treatment, as well as advanced radiotherapy techniques. They also work on lung cancer treatments and mutations, medical imaging techniques and applications, cancer immunotherapy and biomarkers, radiomics and machine learning in medical imaging, and lung cancer research studies.

Frequent publication venues for Suresh Senan include:

  • Radiotherapy and Oncology
  • International Journal of Radiation Oncology*Biology*Physics
  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Lung Cancer

Suresh Senan has collaborated repeatedly with several coauthors, notably Famke L. Schneiders, Idris Bahce, Ben J. Slotman, Chris Dickhoff, and M. Palacios. These collaborations reflect sustained partnerships contributing to a significant number of publications in oncology and radiation therapy.

Among the recent papers associated with Senan's network of research or topics of interest are:

  • Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial, 2020, Journal of Clinical Oncology
  • Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial, 2021, Journal of Thoracic Oncology
  • Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus, 2020, Annals of Oncology
  • Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement, 2020, Radiotherapy and Oncology
  • Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial, 2020, Annals of Oncology

Best Publications

  • Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †

    S Novello;F Barlesi;R Califano;R Califano;T Cufer

  • Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    J. Vansteenkiste;D. De Ruysscher;W.E.E. Eberhardt;E. Lim

  • Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

    David A Palma;Robert Olson;Stephen Harrow;Stewart Gaede

  • Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

    Joe Y Chang;Suresh Senan;Marinus A. Paul;Reza John Mehran

  • Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer

    Berend J Slotman;Corinne Faivre-Finn;Gijs Kramer;Elaine M Rankin

  • Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.

    David A. Palma;Robert Olson;Stephen Harrow;Stewart Gaede

  • Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.

    David A. Palma;Suresh Senan;Kayoko Tsujino;Robert B. Barriger

  • Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non-Small-Cell Lung Cancer

    Frank J. Lagerwaard;Cornelis J.A. Haasbeek;Egbert F. Smit;Ben J. Slotman

  • Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

    Ben J Slotman;Harm van Tinteren;John O Praag;Joost L Knegjens

  • Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

    Tom Treasure;Loic Lang-Lazdunski;David Waller;Judith M Bliss

  • Volumetric intensity-modulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and dosimetric study.

    Wilko F.A.R. Verbakel;Johan P. Cuijpers;Daan Hoffmans;Michael Bieker

  • 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  • Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non–Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis

    David Palma;Otto Visser;Frank J. Lagerwaard;Jose Belderbos

  • Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: A retrospective analysis

    Sashendra Senthi;Frank J Lagerwaard;Cornelis J A Haasbeek;Ben J Slotman

  • PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

    Suresh Senan;Anthony Brade;Lu Hua Wang;Johan Vansteenkiste

  • 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

    W.E.E. Eberhardt;D. De Ruysscher;W. Weder;C. Le Péchoux

  • An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer

    Allison B. Ashworth;Suresh Senan;David A. Palma;Marc Riquet

  • Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.

    Cécile Le Péchoux;Ariane Dunant;Suresh Senan;Aaron Wolfson

  • Outcomes of Stereotactic Ablative Radiotherapy in Patients With Potentially Operable Stage I Non-Small Cell Lung Cancer

    Frank J. Lagerwaard;Naomi E. Verstegen;Cornelis J.A. Haasbeek;Ben J. Slotman

  • Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer

    René W.M. Underberg;Frank J. Lagerwaard;Ben J. Slotman;Johan P. Cuijpers

Frequent Co-Authors

Ben J. Slotman
Ben J. Slotman University of Amsterdam
Egbert F. Smit
Egbert F. Smit VU University Medical Center
Dirk De Ruysscher
Dirk De Ruysscher Maastricht University
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Pieter E. Postmus
Pieter E. Postmus Leiden University Medical Center
Cécile Le Péchoux
Cécile Le Péchoux Institut Gustave Roussy
Everett E. Vokes
Everett E. Vokes University of Chicago
Lawrence B. Marks
Lawrence B. Marks University of North Carolina at Chapel Hill
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering medical study in the USA opens doors to a wide range of online degree options and career upgrades. Many healthcare professionals extend their expertise through flexible programs tailored for working adults. For those focused on healthcare management, accredited mha programs provide essential leadership and administrative skills needed to advance in hospital and clinical settings.

Registered nurses seeking to boost their credentials can enroll in rn to bsn online no clinicals accredited degrees, allowing them to complete their bachelor’s studies without onsite clinical requirements.

For advanced practice nurses, accelerated msn to dnp programs enable fast-track doctoral study, often entirely online. Those looking for efficiency can also explore the shortest dnp program options, making it easier to achieve top clinical or leadership roles without extended time away from work. These pathways help medical professionals flexibly reach career milestones, staying competitive in a rapidly evolving healthcare landscape.

Best Scientists Citing Suresh Senan

Trending Scientists

Recently Published Articles